What does CUSIP 24823R105 represent in this 13F holders report?

CUSIP 24823R105 is the security identifier for DNLI - Denali Therapeutics Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held DNLI - Denali Therapeutics Inc. - Common Stock in Q2 2025?

228 institutional investors reported DNLI - Denali Therapeutics Inc. - Common Stock for Q2 2025. Use the holders table for investor-level position and value details.

Denali Therapeutics Inc. - Common Stock (DNLI)

CUSIP: 24823R105

Q2 2025 13F Holders as of 30 Jun 2025

Security type / class: Equity / Common Stock
Total 13F shares: 137,594,175
Total 13F value: $1,925,023,022
Share change: +4,447,324
Put/Call ratio: 12%
SEC-reported price per share: $13.99
Number of holders: 228
Value change: +$63,128,608
Number of buys: 124
Number of sells: 100
Shares outstanding: 159,469,733

Security key

24823R105

Report period

Q2 2025

Institutions

228

Top holders

DNLI full security history Ownership snapshot Full 13F holder table Denali Therapeutics Inc. SEC filings Denali Therapeutics Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of DNLI - Denali Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

BlackRock, Inc.

Disclosed value leader

BlackRock, Inc.

Comparable rows

15/15

Latest evidence

31 Mar 2025

13F 13D/G Lead comparable stake: 7.2% 13D/G row: BlackRock, Inc. Showing 1-6 of 15 holder rows.

Quick read

BlackRock, Inc. leads the comparable SEC ownership view at 7.2%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock, Inc.'s linked filing trail.

Comparable ownership Top 5

BlackRock, Inc. 7.2%

WELLINGTON MANAGEMENT GROUP LLP 3.9%

Capital Research Global Investors 3.8%

BAILLIE GIFFORD & CO 7.6%

VANGUARD GROUP INC 7.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
BlackRock, Inc.	13F 13D/G Company 13F 13D/G	7.2% from 13D/G	$188,086,226 13,834,956 shares	—	31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP	13F 13D/G Company 13F 13D/G	3.9% from 13D/G	$155,113,484 11,409,598 shares	—	31 Mar 2025
Capital Research Global Investors	13D/G 13F Company 13D/G 13F	3.8%	$90,373,982 5,477,211 shares	$0	31 Dec 2024
BAILLIE GIFFORD & CO	13F Company 13F	7.6%	$164,364,094 12,090,040 shares	—	31 Mar 2025
VANGUARD GROUP INC	13F Company 13F	7.4%	$160,417,696 11,799,757 shares	—	31 Mar 2025
FMR LLC	13F Company 13F	4.6%	$100,784,541 7,413,354 shares	—	31 Mar 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

228

137,594,175

Rows available

228

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

219

Q2 2025 holders

228

Holder diff

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 value	Q2 2025 value	Value change	Value Chg %